Moderna, Inc. (NASDAQ:MRNA) Holdings Boosted by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 170.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,766,398 shares of the company’s stock after purchasing an additional 1,113,455 shares during the period. Pictet Asset Management Holding SA owned approximately 0.46% of Moderna worth $73,447,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Wilmington Savings Fund Society FSB lifted its stake in Moderna by 295.0% in the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Compass Planning Associates Inc acquired a new position in shares of Moderna in the 4th quarter valued at about $37,000. Venturi Wealth Management LLC lifted its position in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after purchasing an additional 664 shares in the last quarter. Crowley Wealth Management Inc. acquired a new stake in shares of Moderna during the fourth quarter worth approximately $41,000. Finally, MassMutual Private Wealth & Trust FSB grew its position in Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock valued at $44,000 after purchasing an additional 389 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Bank of America reduced their price objective on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Citigroup initiated coverage on Moderna in a research report on Thursday, March 13th. They issued a “neutral” rating and a $40.00 target price on the stock. Leerink Partners reduced their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Finally, Morgan Stanley lowered their price target on Moderna from $70.00 to $38.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 15th. Four research analysts have rated the stock with a sell rating, sixteen have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Moderna presently has an average rating of “Hold” and a consensus price target of $59.00.

Moderna Stock Performance

Moderna stock opened at $31.12 on Friday. The business’s 50-day simple moving average is $34.72 and its 200-day simple moving average is $44.38. Moderna, Inc. has a 52 week low of $29.25 and a 52 week high of $170.47. The firm has a market capitalization of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.